Medullary Thyroid CancerNon-Small Cell Lung CancerFirst-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations (in combination with lazertinib)Locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations that has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (in combination with carboplatin and pemetrexed)First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations (in combination with carboplatin and pemetrexed)Locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that has progressed on or after platinum-based chemotherapy (as a single agent)Advanced renal cell carcinomaHepatocellular carcinoma previously treated with sorafenibLocally advanced or metastatic differentiated thyroid cancerWell-differentiated pancreatic neuroendocrine tumorsWell-differentiated extra-pancreatic neuroendocrine tumorsMetastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.Metastatic non-small cell lung cancer (NSCLC) with a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping

All Drugs Targeting MET

Drug	Company	Approved	Indications	Therapeutic Area
CABOMETYX	EXELIXIS INC	2016	5
RYBREVANT	Johnson & Johnson	2021	4
COMETRIQ	EXELIXIS	2012	1
RESNIBEN	AZURITY	-	1
RYBREVANT FASPRO	Johnson & Johnson	2025	1	Oncology
TEPMETKO	EMD SERONO INC	2021	1
ENSACOVE	XCOVERY	2024	1	Oncology
TABRECTA	Novartis	2020	1
RYBREVANT FASPROI	Johnson & Johnson	2026	1	Oncology